September 20, 2019 12:52 PM EDTUpdated September 23, 10:41 AM

Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as Ozempic'

Amber Tong

Novo Nordisk’s priority review voucher on oral semaglutide has paid off. The FDA approval for the GLP-1 drug hit late Friday morning, around six months after the NDA filing.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as Ozempic'

Amber Tong

Sign up to read this article for free.

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

Where the money is: The top 100 venture investors in biotech

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

How AI can address ongoing challenges in the life sciences industry

Here comes the oral GLP-1 drug for di­a­betes — and No­vo Nordisk wants to price Ry­bel­sus 'at a sim­i­lar lev­el as Ozem­pic'

Amber Tong

Sign up to read this article for free.

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as Ozempic'

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

Where the money is: The top 100 venture investors in biotech

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

How AI can address ongoing challenges in the life sciences industry